Glucotrack Inc (GCTK)

$0.16 0.00 (-1.17%)
Market Cap 4.30M
Revenue (ttm) 0.00
Net Income (ttm) -22.60M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio -0.02
Volume 644,900
Avg Vol 4,391,660
Day's Range N/A - N/A
Shares Out 25.59M
Stochastic %K 59%
Beta 0.02
Analysts Strong Buy
Price Target N/A

Latest News on GCTK

Glucotrack to Participate in FORGETDIABETES, a Prominent European Research Initiative to Develop a Bionic Pancreas

Apr 16, 2025, 8:00 AM EDT - 12 days ago

Glucotrack to Participate in FORGETDIABETES, a Prominent European Research Initiative to Develop a Bionic Pancreas

Glucotrack and OneTwo Analytics to Collaborate for Clinical Study Analysis on Its Continuous Blood Glucose Monitor

Apr 3, 2025, 8:01 AM EDT - 25 days ago

Glucotrack and OneTwo Analytics to Collaborate for Clinical Study Analysis on Its Continuous Blood Glucose Monitor

Glucotrack Reports Full Year 2024 Financial Results and Recent Corporate Highlights

Mar 31, 2025, 5:00 PM EDT - 27 days ago

Glucotrack Reports Full Year 2024 Financial Results and Recent Corporate Highlights

Glucotrack to Present First-In-Human Study Results for Continuous Blood Glucose Monitor at the 2025 International Conference on Advanced Technologies & Treatment for Diabetes

Mar 19, 2025, 8:01 AM EDT - 5 weeks ago

Glucotrack to Present First-In-Human Study Results for Continuous Blood Glucose Monitor at the 2025 International Conference on Advanced Technologies & Treatment for Diabetes

Glucotrack Appoints Guillermo Umpierrez, MD, CDCES, FACE, MACP as New Medical Advisory Board Member

Feb 26, 2025, 8:01 AM EST - 2 months ago

Glucotrack Appoints Guillermo Umpierrez, MD, CDCES, FACE, MACP as New Medical Advisory Board Member

Glucotrack, Inc. Announces Pricing of $3.0 Million Public Offering

Feb 4, 2025, 12:24 PM EST - 2 months ago

Glucotrack, Inc. Announces Pricing of $3.0 Million Public Offering

Glucotrack Announces Successful Completion of Its First Human Clinical Study of Continuous Blood Glucose Monitor

Feb 4, 2025, 8:01 AM EST - 2 months ago

Glucotrack Announces Successful Completion of Its First Human Clinical Study of Continuous Blood Glucose Monitor

Glucotrack Strengthens Leadership Team with Appointment of New Chief Financial Officer

Jan 29, 2025, 9:00 AM EST - 3 months ago

Glucotrack Strengthens Leadership Team with Appointment of New Chief Financial Officer

Glucotrack Announces ISO 13485:2016 Certification

Jan 21, 2025, 8:01 AM EST - 3 months ago

Glucotrack Announces ISO 13485:2016 Certification

Glucotrack Strenghtens Leadership Team with Addition of Industry Veteran as Vice President of Regulatory Affairs

Jan 15, 2025, 8:01 AM EST - 3 months ago

Glucotrack Strenghtens Leadership Team with Addition of Industry Veteran as Vice President of Regulatory Affairs

Glucotrack to Present at TechBio Showcase™ 2025

Jan 7, 2025, 4:05 PM EST - 3 months ago

Glucotrack to Present at TechBio Showcase™ 2025

GLUCOTRACK ANNOUNCES START OF ENROLLMENT FOR HUMAN CLINICAL STUDY OF CONTINUOUS BLOOD GLUCOSE MONITOR

Dec 3, 2024, 8:30 AM EST - 5 months ago

GLUCOTRACK ANNOUNCES START OF ENROLLMENT FOR HUMAN CLINICAL STUDY OF CONTINUOUS BLOOD GLUCOSE MONITOR

Glucotrack, Inc. Announces Closing of $10.0 Million Public Offering and Concurrent Private Placement Converting $4.0 in Outstanding Debt

Nov 14, 2024, 4:30 PM EST - 5 months ago

Glucotrack, Inc. Announces Closing of $10.0 Million Public Offering and Concurrent Private Placement Converting $4.0 in Outstanding Debt

GLUCOTRACK TO PRESENT AT 2024 BIOFUTURE CONFERENCE

Oct 22, 2024, 9:00 AM EDT - 6 months ago

GLUCOTRACK TO PRESENT AT 2024 BIOFUTURE CONFERENCE

GLUCOTRACK ANNOUNCES ORAL & POSTER PRESENTATIONS AT THE 2024 DIABETES TECHNOLOGY MEETING

Oct 1, 2024, 9:00 AM EDT - 7 months ago

GLUCOTRACK ANNOUNCES ORAL & POSTER PRESENTATIONS AT THE 2024 DIABETES TECHNOLOGY MEETING

JOHN BALLANTYNE, FORMER BIOTECHNOLOGY EXECUTIVE, JOINS THE GLUCOTRACK BOARD OF DIRECTORS

Sep 3, 2024, 9:00 AM EDT - 8 months ago

JOHN BALLANTYNE, FORMER BIOTECHNOLOGY EXECUTIVE, JOINS THE GLUCOTRACK BOARD OF DIRECTORS

Glucotrack's Innovative Blood Glucose Monitoring Concept Resonates with Patients with Diabetes, According to New Survey Presented at Association of Diabetes Care and Education Specialists (ADCES) 2024 Annual Conference

Aug 15, 2024, 9:00 AM EDT - 9 months ago

Glucotrack's Innovative Blood Glucose Monitoring Concept Resonates with Patients with Diabetes, According to New Survey Presented at Association of Diabetes Care and Education Specialists (ADCES) 2024 Annual Conference

GLUCOTRACK ANNOUNCES POSTER PRESENTATION ON CONTINUOUS BLOOD GLUCOSE MONITOR SURVEY DATA AT THE ASSOCIATION OF DIABETES CARE AND EDUCATION SPECIALISTS (ADCES) 2024 ANNUAL CONFERENCE

Aug 5, 2024, 9:00 AM EDT - 9 months ago

GLUCOTRACK ANNOUNCES POSTER PRESENTATION ON CONTINUOUS BLOOD GLUCOSE MONITOR SURVEY DATA AT THE ASSOCIATION OF DIABETES CARE AND EDUCATION SPECIALISTS (ADCES) 2024 ANNUAL CONFERENCE

GLUCOTRACK ANNOUNCES THE APPOINTMENT OF ANDY BALO TO BOARD OF DIRECTORS

Jun 20, 2024, 8:30 AM EDT - 11 months ago

GLUCOTRACK ANNOUNCES THE APPOINTMENT OF ANDY BALO TO BOARD OF DIRECTORS

GLUCOTRACK REPORTS SUCCESSFUL COMPLETION OF FIRST REPORTED LONG-TERM PRECLINICAL STUDY OF ITS EPIDURAL GLUCOSE MONITORING SENSOR

Jun 13, 2024, 9:19 AM EDT - 11 months ago

GLUCOTRACK REPORTS SUCCESSFUL COMPLETION OF FIRST REPORTED LONG-TERM PRECLINICAL STUDY OF ITS EPIDURAL GLUCOSE MONITORING SENSOR

GLUCOTRACK TO PRESENT IN THE JUNE 2024 SIDOTI SMALL CAP CONFERENCE

Jun 10, 2024, 10:50 AM EDT - 11 months ago

GLUCOTRACK TO PRESENT IN THE JUNE 2024 SIDOTI SMALL CAP CONFERENCE

GLUCOTRACK ANNOUNCES 90-DAY PRECLINICAL STUDY RESULTS THAT DEMONSTRATE SUSTAINED ACCURACY OF ITS IMPLANTABLE CONTINUOUS BLOOD GLUCOSE MONITOR

Jun 5, 2024, 8:30 AM EDT - 11 months ago

GLUCOTRACK ANNOUNCES 90-DAY PRECLINICAL STUDY RESULTS THAT DEMONSTRATE SUSTAINED ACCURACY OF ITS IMPLANTABLE CONTINUOUS BLOOD GLUCOSE MONITOR

GLUCOTRACK'S EPIDURAL GLUCOSE MONITORING SENSOR DEMONSTRATES SUCCESSFUL 30-DAY SAFETY & PERFORMANCE IN LONG-TERM PRECLINICAL STUDY

May 16, 2024, 8:30 AM EDT - 1 year ago

GLUCOTRACK'S EPIDURAL GLUCOSE MONITORING SENSOR DEMONSTRATES SUCCESSFUL 30-DAY SAFETY & PERFORMANCE IN LONG-TERM PRECLINICAL STUDY

GLUCOTRACK ANNOUNCES REVERSE STOCK SPLIT

May 15, 2024, 4:15 PM EDT - 1 year ago

GLUCOTRACK ANNOUNCES REVERSE STOCK SPLIT

GLUCOTRACK ANNOUNCES ABSTRACTS ACCEPTED FOR POSTER PRESENTATION AT 84TH SCIENTIFIC SESSIONS OF THE AMERICAN DIABETES ASSOCIATION

May 2, 2024, 9:00 AM EDT - 1 year ago

GLUCOTRACK ANNOUNCES ABSTRACTS ACCEPTED FOR POSTER PRESENTATION AT 84TH SCIENTIFIC SESSIONS OF THE AMERICAN DIABETES ASSOCIATION

GLUCOTRACK ANNOUNCES CLOSING OF PRIVATE PLACEMENT

Apr 22, 2024, 2:10 PM EDT - 1 year ago

GLUCOTRACK ANNOUNCES CLOSING OF PRIVATE PLACEMENT

GLUCOTRACK ANNOUNCES EXPANSION OF ITS CONTINUOUS GLUCOSE MONITORING TECHNOLOGY TO EPIDURAL GLUCOSE MONITORING

Apr 16, 2024, 8:30 AM EDT - 1 year ago

GLUCOTRACK ANNOUNCES EXPANSION OF ITS CONTINUOUS GLUCOSE MONITORING TECHNOLOGY TO EPIDURAL GLUCOSE MONITORING

GLUCOTRACK ANNOUNCES INCREASED SENSOR LONGEVITY FOR ITS IMPLANTABLE CONTINUOUS BLOOD GLUCOSE MONITOR

Apr 2, 2024, 8:30 AM EDT - 1 year ago

GLUCOTRACK ANNOUNCES INCREASED SENSOR LONGEVITY FOR ITS IMPLANTABLE CONTINUOUS BLOOD GLUCOSE MONITOR

GLUCOTRACK EXPANDS LEADERSHIP TEAM WITH NEW VICE PRESIDENT OF QUALITY

Mar 12, 2024, 9:30 AM EDT - 1 year ago

GLUCOTRACK EXPANDS LEADERSHIP TEAM WITH NEW VICE PRESIDENT OF QUALITY

GLUCOTRACK SELECTS CIRTEC MEDICAL AS MANUFACTURER FOR ITS IMPLANTABLE CONTINUOUS BLOOD GLUCOSE MONITOR

Feb 27, 2024, 8:30 AM EST - 1 year ago

GLUCOTRACK SELECTS CIRTEC MEDICAL AS MANUFACTURER FOR ITS IMPLANTABLE CONTINUOUS BLOOD GLUCOSE MONITOR

GLUCOTRACK ANNOUNCES THE APPOINTMENT OF LUIS MALAVÉ TO CHAIR OF THE BOARD OF DIRECTORS

Feb 13, 2024, 9:30 AM EST - 1 year ago

GLUCOTRACK ANNOUNCES THE APPOINTMENT OF LUIS MALAVÉ TO CHAIR OF THE BOARD OF DIRECTORS

GLUCOTRACK ANNOUNCES EARLY ACCURACY DATA FOR ITS IMPLANTABLE CONTINUOUS GLUCOSE MONITOR

Jan 2, 2024, 12:33 PM EST - 1 year ago

GLUCOTRACK ANNOUNCES EARLY ACCURACY DATA FOR ITS IMPLANTABLE CONTINUOUS GLUCOSE MONITOR

GLUCOTRACK ANNOUNCES 180-DAY EXTENSION TO REGAIN COMPLIANCE WITH NASDAQ MINIMUM BID PRICE REQUIREMENT

Nov 30, 2023, 5:39 PM EST - 1 year ago

GLUCOTRACK ANNOUNCES 180-DAY EXTENSION TO REGAIN COMPLIANCE WITH NASDAQ MINIMUM BID PRICE REQUIREMENT

GLUCOTRACK ANNOUNCES SHAREHOLDER UPDATE

Nov 13, 2023, 9:00 AM EST - 1 year ago

GLUCOTRACK ANNOUNCES SHAREHOLDER UPDATE

GLUCOTRACK ANNOUNCES PRECLINICAL TESTING WITH IMPLANTABLE CONTINUOUS GLUCOSE MONITOR

Oct 12, 2023, 8:30 AM EDT - 1 year ago

GLUCOTRACK ANNOUNCES PRECLINICAL TESTING WITH IMPLANTABLE CONTINUOUS GLUCOSE MONITOR

GLUCOTRACK ANNOUNCES THE APPOINTMENT OF ERIN CARTER TO BOARD OF DIRECTORS

Aug 31, 2023, 8:30 AM EDT - 1 year ago

GLUCOTRACK ANNOUNCES THE APPOINTMENT OF ERIN CARTER TO BOARD OF DIRECTORS

GLUCOTRACK ANNOUNCES NEW VP OF MARKETING

Aug 28, 2023, 9:00 AM EDT - 1 year ago

GLUCOTRACK ANNOUNCES NEW VP OF MARKETING

GLUCOTRACK ANNOUNCES POSITIVE DATA FROM FEASIBILITY STUDY FOR IMPLANTABLE CONTINUOUS GLUCOSE MONITOR

Jul 25, 2023, 9:00 AM EDT - 1 year ago

GLUCOTRACK ANNOUNCES POSITIVE DATA FROM FEASIBILITY STUDY FOR IMPLANTABLE CONTINUOUS GLUCOSE MONITOR

Aegis Capital Corp. Acted as Sole Bookrunner on a $10 Million Underwritten Public Offering for GlucoTrack, Inc. (NASDAQ: GCTK)

Apr 17, 2023, 11:05 AM EDT - 2 years ago

Aegis Capital Corp. Acted as Sole Bookrunner on a $10 Million Underwritten Public Offering for GlucoTrack, Inc. (NASDAQ: GCTK)

GlucoTrack Closes $10 Million Underwritten Public Offering of Common Stock

Apr 17, 2023, 9:15 AM EDT - 2 years ago

GlucoTrack Closes $10 Million Underwritten Public Offering of Common Stock

GlucoTrack Announces Pricing of $10 Million Underwritten Public Offering of Common Stock

Apr 13, 2023, 9:22 AM EDT - 2 years ago

GlucoTrack Announces Pricing of $10 Million Underwritten Public Offering of Common Stock

GlucoTrack Announces Proposed Underwritten Public Offering of Common Stock

Apr 12, 2023, 5:50 PM EDT - 2 years ago

GlucoTrack Announces Proposed Underwritten Public Offering of Common Stock

GLUCOTRACK PROVIDES SHAREHOLDER UPDATE

Mar 14, 2023, 10:00 AM EDT - 2 years ago

GLUCOTRACK PROVIDES SHAREHOLDER UPDATE

GLUCOTRACK ANNOUNCES THE HIRING OF DR. MARK TAPSAK

Oct 14, 2022, 9:45 AM EDT - 2 years ago

GLUCOTRACK ANNOUNCES THE HIRING OF DR. MARK TAPSAK

GLUCOTRACK TO BEGIN RESEARCH & DEVELOPMENT OF NOVEL CONTINUOUS GLUCOSE MONITORING SYSTEM

Oct 10, 2022, 8:30 AM EDT - 2 years ago

GLUCOTRACK TO BEGIN RESEARCH & DEVELOPMENT OF NOVEL CONTINUOUS GLUCOSE MONITORING SYSTEM

GlucoTrack, Inc. Provides Development Update on its Gen 2 Non-Invasive Glucose Monitor

Jun 22, 2022, 8:30 AM EDT - 3 years ago

GlucoTrack, Inc. Provides Development Update on its Gen 2 Non-Invasive Glucose Monitor

GlucoTrack, Inc. Announces Effectiveness of Corporate Name Change and Ticker Symbol Change

Mar 14, 2022, 9:15 AM EDT - 3 years ago

GlucoTrack, Inc. Announces Effectiveness of Corporate Name Change and Ticker Symbol Change

Integrity Applications Issues Shareholder Update Letter

Dec 20, 2021, 11:57 AM EST - 3 years ago

Integrity Applications Issues Shareholder Update Letter

Integrity Applications Announces Uplisting to Nasdaq Capital Market

Dec 8, 2021, 8:30 AM EST - 3 years ago

Integrity Applications Announces Uplisting to Nasdaq Capital Market

Integrity Applications, Inc. Expands U.S. Operations with the hiring of James P. Thrower, PhD, as Vice President of Engineering

Dec 6, 2021, 9:36 AM EST - 3 years ago

Integrity Applications, Inc. Expands U.S. Operations with the hiring of James P. Thrower, PhD, as Vice President of Engineering